Purpose To determine the utility of 18F-fluoro-l-3,4-dihydroxy-phenylalanine (18F-DOPA) PET/MRI versus cross-sectional MRI alone in glioma response assessment and identify whether the two techniques demonstrate different tumour features. Methods 18F-DOPA PET/MRI studies from 40 patients were analysed. Quantitative PET parameters and conventional MRI features were recorded. Tumour volume was assessed on both PET and MRI. Using dynamic susceptibility contrast perfusion-weighted imaging, maps of cerebral blood flow (CBF) and cerebral blood volume (CBV) were obtained. Within volume of tumours of tumour features and normal-appearing white matter (NAWM) drawn on MRI, standardised uptake value (SUV)max, CBF and CBV were recorded. Presence of residual active tumour was assessed by qualitative visual assessment. Receiver operating characteristic analysis was performed univariately and on parameter combination to analyse ability to determine presence/absence of disease. Reference standard for presence of viable tissue was biopsy or clinical follow-up. Results Median SUVmax was 3.4 for low-grade glioma (LGG) and 3.3 for high-grade glioma (HGG). There was a significant correlation between PWI parameters and WHO grade (P < 0.001), but no correlation with SUVmax. Median 18F-DOPA volume was 8216.88 mm3 for HGG and 6284.94 mm3 for LGG; MRI volume was 6316.57 mm3 and 5931.55 mm3, respectively. SUVmax analysis distinguished enhancing and nonenhancing components from necrosis and NAWM and demonstrated active disease in nonenhancing regions. Visually, the modalities were concordant in 37 patients. Combining the multiparametric PET/MRI approach with all available data-enhanced detection of the presence of tumour (area under the curve 0.99, P < 0.01). Conclusion MRI and 18F-DOPA are complementary modalities for assessment of tumour burden. Matching 18F-DOPA and MRI in assessing residual tumour volume may better delineate the radiotherapy target volume.
The use of multiparametric 18F-fluoro- l -3,4-dihydroxy-phenylalanine PET/MRI in post-therapy assessment of patients with gliomas
Zaccagna F.;
2020
Abstract
Purpose To determine the utility of 18F-fluoro-l-3,4-dihydroxy-phenylalanine (18F-DOPA) PET/MRI versus cross-sectional MRI alone in glioma response assessment and identify whether the two techniques demonstrate different tumour features. Methods 18F-DOPA PET/MRI studies from 40 patients were analysed. Quantitative PET parameters and conventional MRI features were recorded. Tumour volume was assessed on both PET and MRI. Using dynamic susceptibility contrast perfusion-weighted imaging, maps of cerebral blood flow (CBF) and cerebral blood volume (CBV) were obtained. Within volume of tumours of tumour features and normal-appearing white matter (NAWM) drawn on MRI, standardised uptake value (SUV)max, CBF and CBV were recorded. Presence of residual active tumour was assessed by qualitative visual assessment. Receiver operating characteristic analysis was performed univariately and on parameter combination to analyse ability to determine presence/absence of disease. Reference standard for presence of viable tissue was biopsy or clinical follow-up. Results Median SUVmax was 3.4 for low-grade glioma (LGG) and 3.3 for high-grade glioma (HGG). There was a significant correlation between PWI parameters and WHO grade (P < 0.001), but no correlation with SUVmax. Median 18F-DOPA volume was 8216.88 mm3 for HGG and 6284.94 mm3 for LGG; MRI volume was 6316.57 mm3 and 5931.55 mm3, respectively. SUVmax analysis distinguished enhancing and nonenhancing components from necrosis and NAWM and demonstrated active disease in nonenhancing regions. Visually, the modalities were concordant in 37 patients. Combining the multiparametric PET/MRI approach with all available data-enhanced detection of the presence of tumour (area under the curve 0.99, P < 0.01). Conclusion MRI and 18F-DOPA are complementary modalities for assessment of tumour burden. Matching 18F-DOPA and MRI in assessing residual tumour volume may better delineate the radiotherapy target volume.File | Dimensione | Formato | |
---|---|---|---|
fraioli2020.pdf
accesso riservato
Tipo:
Versione (PDF) editoriale
Licenza:
Licenza per accesso riservato
Dimensione
895.74 kB
Formato
Adobe PDF
|
895.74 kB | Adobe PDF | Visualizza/Apri Contatta l'autore |
Fraioli_2020.pdf
accesso aperto
Tipo:
Postprint
Licenza:
Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale - Non opere derivate (CCBYNCND)
Dimensione
782.92 kB
Formato
Adobe PDF
|
782.92 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.